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Genetic studies of familial schizophrenia in Finland have observed significant
associations with a group of biologically related genes,DISC1,NDE1,NDEL1,
PDE4B and PDE4D, the ‘DISC1 network’. Here, we use gene expression and
psychoactive medication use data to study their biological consequences and
potential treatment implications. Gene expression levels were determined in
64 individuals from 18 families, while prescription medication information
has been collected over a 10-year period for 931 affected individuals.
We demonstrate that the NDE1 SNP rs2242549 associates with significant
changes in gene expression for 2908 probes (2542 genes), of which 794
probes (719 genes) were replicable. A significant number of the genes altered
were predicted targets of microRNA-484 ( p ¼ 3.0  1028), located on a
non-coding exon of NDE1. Variants within the NDE1 locus also displayed
significant genotype by gender interaction to early cessation of psychoactive
medications metabolized by CYP2C19. Furthermore, we demonstrate that
miR-484 can affect the expression of CYP2C19 in a cell culture system. Thus,
variation at the NDE1 locus may alter risk of mental illness, in part through
modification of miR-484, and such modification alters treatment response to
specific psychoactive medications, leading to the potential for use of this
locus in targeting treatment.1. Introduction
The identificationofgenes that predispose to complexpsychiatric traits is an impor-
tant aspect in studying these conditions, however it is vital that this information is
then used to improve our biological understanding and ultimately the treatment
procedures for the disorders. This can be achieved through genetic studies in
which, instead of using an end state diagnosis, alternative traits are employed
that can measure a biological or pharmacological aspect of the condition.
Polygenic disorders, such as schizophrenia, are influenced by numerous inter-
acting genetic factors, therefore identification of one candidate gene may aid in
identification of others. This approach has been used in a large Finnish family
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viously associated with schizophrenia [1,2], and which led to
observation of association with four other genes (NDE1,
NDEL1, PDE4B and PDE4D) [3,4] that encode protein binding
partners of the DISC1 protein [5–8]. The idea that such protein
interaction partners of DISC1 are encoded for by genes which
show genetic interaction in mental illness is termed the DISC1
network hypothesis. Specifically, multiple associations for
psychiatric [2,9–11] and related endophenotypes, including
memory [12], cognitive and neuroimaging [13] phenotypes,
have been reported forDISC1 in Finnish cohorts. By condition-
ing genome-wide linkage data for schizophrenia on DISC1, a
peak of linkage at chromosome 16p was observed [3], near to
NDE1 (nuclear distribution element 1). This was followed up
through association analysis at the NDE1 locus, leading to the
observation that a haplotype and its constituent SNPs associate
with schizophrenia in this cohort, in a gender-dependent
manner [3]. Genetic association for schizophrenia was, there-
fore, tested for other DISC1 binding partners in this family
cohort [4]. Although SNPs and haplotypes from six other
genes were initially observed to associate, only variants in
NDEL1 (NDE-like 1, a close paralogue of NDE1) and in the
phosphodiesterases PDE4B and PDE4D replicated when
tested in a second, distinct sample from the cohort [4]. Recently,
through further investigation of the roles of these variants in the
DISC1 network, theNDE1 locus has been identified to increase
risk of schizophrenia in this Finnish family cohort through
interaction with high birth weight, a promising proxy measure
for multiple pre- and/or perinatal environments [14].
The role of the DISC1 network as a source of genetic risk for
neuropsychiatric disorders is controversial due to the absence,
to date, of evidence for their involvement in population based
genomic studies of common variation [15,16]. However,
these genes have been implicated at least within specific popu-
lations through strong evidence emerging from family based
approaches and the studies of rare variants. In addition to the
evidence from the Finnish family cohort, the DISC1 and
PDE4B genes are disrupted by chromosomal aberrations in
Scottish families with major mental illness [8,17,18]. Further-
more, NDE1 is independently implicated in major mental
illness through its presence at 16p13.11, which is subject to
duplications in schizophrenia [19–22], as well as being directly
implicated through rare SNPs in patients [23]. The importance
of the NDE1 protein for neurodevelopment more generally
has been dramatically demonstrated in individuals with
biallelic loss of the functional NDE1 gene, leading to severe
microcephaly phenotypes, sometimes described in conjunction
with lissencephaly or hydrocephaly [24–27]. Deletion of only
one copy of the 16p13.11 locus, meanwhile, has been associated
with neurological conditions including autism and epilepsy
[28]. Recently it was shown that expression of mature miR-
484, a microRNA that is encoded on an untranslated exon of
NDE1, led to alterations in neural progenitor proliferation and
differentiation, as well as behavioural changes in mice, thus
implicating the microRNA in the phenotypes associated with
16p13.11 duplication [29].
We have previously studied the effect of DISC1 network
genetic variation on gene expression in a small (n ¼ 30) pub-
licly available population cohort of the CEU (Utah residents
with North and Western European ancestry) individuals.
Using gene expression measured on the same individuals, by
different laboratories, we were able to observe 528 genes as
being replicable in their differential expression across 24variants studied, of which 35 genes had pre-existing support-
ing evidence for a role in psychosis [30]. Intriguingly, seven
of these affected genes were noted to be targets for drugs pre-
scribed for psychiatric illness, leading to the hypothesis that
these DISC1 network variants, through their action on gene
expression, may alter treatment outcome for medications
designed to target these genes [30].
Here, in order to advance our understanding of the role
these genes play in the aetiology of schizophrenia in Finland,
we take this approach further. This is accomplished by using
data on gene expression levels in case families in which these
DISC1 network genetic variants have been previously demon-
strated to associate with schizophrenia [1–4], as well as by
using data collected on how different psychoactive medications
are used by the affected individuals within these families.2. Material and methods
2.1. Study samples
The principal samples used here are part of a larger study of
familial schizophrenia. These are Finnish patients born between
1940 and 1976, who were identified through the hospital dis-
charge, disability pension and free medication registers [1,31].
The cohort totals 458 families (498 nuclear families) that contain
2756 individuals, of whom 2059 have been previously geno-
typed for the DISC1 network genes [1–4]. Of these genotyped
individuals, 931 are classified as affected with major mental ill-
nesses using criteria from the Diagnostic and Statistical Manual
ofMentalDisorders, fourth edition (DSM-IV) [32]. These include
635 diagnosed with schizophrenia, 125 with schizoaffective dis-
order, 95 with schizophrenia spectrum diagnoses and 76 with
other mental illnesses, including bipolar disorder and major
depression. Here, two sub-sets of this larger familial sample
were used as discovery cohorts, firstly a sample of 18 families
(64 individuals, 23 broadly affected: 15 with schizophrenia,
three with schizoaffective disorder, three with schizophrenia
spectrum diagnoses, and two with other mental illnesses; 41
unaffected family members) for whom RNA was available to
study gene expression level changes, and secondly all 931
broadly affected individuals were used to studymedication use.
In order to replicate the gene expression results obtained
from this family data, two independent cohorts were used.
The first of these replication cohorts was a Finnish discordant
twin pair sample ascertained for schizophrenia (N ¼ 73), for
which information about recruitment and clinical evaluation
has been described previously [33]. Briefly, the participants
are 18 schizophrenia patients, their 18 unaffected co-twins
and 37 control twins who have provided blood samples for
gene expression analysis (N ¼ 73). The second replication
cohort was the Genotype-Tissue Expression (GTEx) database
(N ¼ 338), a publicly available resource for exploring the corre-
lation between genotypes and gene expression across multiple
tissues and in a genome-wide manner (accessed on 2 Septem-
ber 2016, www.gtexportal.org/home) [34]. To best match the
source of the RNA used in the discovery cohort studies, data
from whole blood were used for the GTEx tests.
2.2. Gene expression data
Total RNA was extracted from fresh blood samples from 82
individuals, with 18 individuals excluded from further analysis
as their samples’ RNA integrity number was lower than 8.
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toprovideRNAforgeneexpression analysisbasedonprior gen-
etic observations in these families including DISC1 [1], RELN
[35] and TOP3B [36]. Genome-wide gene expression measures
were assayed for this discovery cohort using the Illumina
HumanHT-12 v4.0 Expression BeadChip. Of the 48 212 probes
on the chip, 11 976 were significantly detectable at a threshold
of p  0.01 in more than 90% of individuals. The expression
data for these probes were processed using quantile normaliza-
tion followed by log2 transformation. Raw anonymous data
regarding this family cohort can be accessed at the Gene
ExpressionOmnibus (GEO) database (GSE48072). For the repli-
cation twin cohort (N ¼ 73), genome-wide gene expressiondata
have beenmeasured using the IlluminaHumanWG6 v3.0 chip,
as reported previously in detail [37]. After quality control and
data processing, identical to that used on the family data, 18
559 probes from this chip were significantly detectable.
2.3. Genotyping
In the discovery sub-cohorts used here, both genotype and
expression data were available from 39 individuals, while 931
individuals had both genotype and medication data available.
Thus, in order to ensure sufficient numbers of individuals for
statistical testing, we only studied genetic variants that met
specific minor allele homozygote frequencies in these sub-
cohorts. In the discovery cohort for gene expression, a cut-off
value for the minor allele homozygote frequency of 10%
was implemented, providing five variants (DISC1: HEP3 hap-
lotype (comprising SNPs rs751229 and rs3738401) and
rs821616; NDE1: rs4781678, rs2242549 and rs1050162) with
which to perform the analysis. For the discovery cohort for
medication use, the frequency of the genetic variants was
restricted to those with a minor allele homozygote frequency
of at least 5%. This allowed seven variants from three DISC1
network genes to be studied (DISC1: rs821616; NDE1:
rs4781678, rs2242549, rs881803, rs2075512, and the haplotype
of these four SNPs ‘NDE1 Tag haplotype’; PDE4B: rs7412571)
The genotypes for the replication cohort of discordant
twins were produced with the same method and at the same
time as those described previously [1,3,4], with only two var-
iants analysed (NDE1: rs2242549 and rs1050162) using the
gene expression data. The analysis using the GTEx database
as a replication cohort was conducted for all variants studied
in the families, except for the DISC1 haplotype.
All genetic variants analysed in this study have been impli-
cated by previously described evidence as being associated
with the aetiology of schizophrenia in this cohort [1–4], with
variants in both DISC1 and NDE1 having displayed prior
gender-dependent effects [1,3,12]. Therefore, no multiple test
correction has been applied to correct for the multiple testing
across variants or gender interaction models, as they can all
be considered hypothesis based. However, because we are
screening alternative phenotypes in a hypothesis-free manner,
we have applied the measures described in the following
sections in order to further characterize these a priori variants.
2.4. Association between genome-wide expression
levels and genotypes
For the discovery cohort used to study gene expression, a
mixed effect linear regression model was fitted for eachprobe and genotype using R (RStudio version 0.99.489)
lme4 package [38], after correcting for gender, age, diagnostic
status and family or twin status effects as a covariate. This
analysis was performed separately but identically for the dis-
covery cohort and the replication twin cohort. We used the
false discovery rate (FDR) method in place of a family-wise
error rate (FWER). FDR is widely applied for microarray ana-
lyses because it allows more genes to be extracted for further
exploration, and was performed using the qvalue package in
R [39] to estimate the FDRs of q  0.05. The post hoc power of
our small familial discovery cohort to detect gene expression
changes was estimated using R package ssize.fdr [40]. The
GTEx database was mined using its own in-built test pro-
cedure, entering in a list of gene IDs to be tested against
our SNPs of interest. Data from whole blood was used in
order to replicate only those genes identified as significantly
altered in their gene expression levels at a cut-off of p  0.05.
When testing for replication, probes significant ( p  0.05) in
the discovery cohort prior to application of FDR were
studied. See figure 1 for a flow chart of analysis.
2.5. MicroRNA target prediction and enrichment
analysis
A comprehensive list of predicted 30UTR targets for miR-484
were obtained from the miRWalk database [41], considering
only genes predicted by at least six of the 12 programs. Inge-
nuity pathway analysis (QIAGEN Redwood City, www.
qiagen.com/ingenuity) was used to analyse potential enrich-
ment of these genes among those significantly altered in
their expression levels by NDE1 SNPs in the discovery and
replication cohorts.
2.6. Medication data
Prescription medication data from the 931 affected individuals
of the schizophrenia family cohort for the period 1 January 1996
to 31 December 2005 was obtained from the Finnish National
Prescription Register of the National Social Insurance Insti-
tution (SII) [42], thus forming the discovery cohort for
medication use. In this cohort ‘medication use’ is based on pur-
chases of prescribed psychoactive drugs for which the SII have
paid a reimbursement. Data from this register contain infor-
mation on date of purchase and the dose, stated as the
international standard daily defined dose. Thus, using this
data, medication periods were defined according to method 4
proposed by Mantel-Teeuwisse et al. [43], multiplying defined
daily dose by a factor of 1.1 and filling 15-day gaps between
medication periods. This medication period data was used to
determine the probability of cessation of each drug by genotype
and converted into a binary variable using three months as a
cut-off. This three months cut-off reflects that an individual
either purchased more of the same medication, or purchased
a different medication within a three-month period after the
original purchase date. Only psychoactive medications with
at least 15 instances of use for three months or less were
taken for association analysis of the individual drugs, meaning
that, of the possible 101 psychoactive drugs for which datawas
available, only 24 were analysed. When data from multiple
drugs were combined in order to study classes of medication,
all medications for which data are available were used, regard-
less of individual frequency. In order to account for the fact that
DISC1 network genes associated with schizophrenia in Finnish families
DISC1, NDE1, NDEL1, PDE4B and PDE4D
gene expression study:
64 individuals from 18 families
11 976 probes Illumina HumanHT-12
a priori results:
6 genes out of 86 prior observations
genome wide scan results:
2908 probes (2542 genes) with NDE1
variant rs2242549 (FDR £5%)
replication of results:
NDE1 variants in LD = 695 genes
Finnish twin cohort = 56 genes
GTEx (whole blood) = 180 genes
medication groups:
groups of medications based on the
classification criteria (5 groups)
medication screen:
24 medications used frequently
between 1999 and 2009
medication study:
931 affected individuals
7 genetic variants from 3 genes
gender interaction analysed
(DISC1, NDE1, PDE4B)
of 7 CYP2C19
metabolized drugs,
4 are SSRIs
microRNA enrichment:
genes identified as altered are
enriched for targets for miR-484
rs2242549 associated genes (3.0 × 10–8)
cell culture model to verify effect of miR-484 on protein levels of:
CYP2C19 versus CYP2D6 (does miR-484 alter expression of CYP2C19 exclusively?)
TRIOBP (does miR-484 alter the expression of genes identified here but not replicated?)
NDE1 (does miR-484 alter the expression of genes not identified in our discovery cohort?)
replicated in Finnish cohorts:
NDE1 variants in LD (1.2 × 10–3)
Finnish twin cohort (1.4 × 10–3)
4 replicated across all cohorts
FCER1G, KIAA1468, ST3GAL5,
SULT1A1, TRIOBP and ZNF500
v4.0 expression BeadChip
5 genetic variants from DISC1 and NDE1
N
D
E1
miR-484 CYP2C19
CYP2C19
metabolized by CYP2C19 (7 drugs*)
classified as an SSRI (6 drugs)
combinations of these (below)
NDE1 variants associate with
levomepromazine, diazepam and
citalopram (two metabolized by CYP2C19)
SSRI
3 3 3
*sertraline removed for sub-groups
(electronic supplementary material, table S3)
TR
IO
BP
Figure 1. Schematic flow chart of the analyses undertaken in this study.
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analysis of the medication usage used logistic regression with
GEE-estimation (generalized estimating equations), as used
by the geepack package for R [44,45]. Bonferroni correction
was used to correct for the multiple tests in the analysis of the
individualmedications (24 tests) and the groups ofmedications
(five tests).While p-values are presented unadjusted, only those
that would surpass the Bonferroni correction-based thresholds
(p  0.0021 and p  0.01, respectively) are highlighted. See
figure 1 for a flow chart of analysis.
2.7. Cell culture and western blotting
To determine whether miR-484 had the potential to affect the
expression of selected proteins in a human cell-based system,
NLF neuroblastoma cells (Children’s Hospital of Philadelphia)
were grown in RPMI 1640/10% fetal calf serum/2 mM
L-glutamine (all fromThermo Fischer Scientific) and transfected
with 50 nM of either a mimic of mature miR-484 (QIAGEN,
Sy-hsa-miR-484) or a negative control microRNA (QIAGEN,AllStars Negative Control microRNA) using Lipofectamine
2000 (Thermo Fischer Scientific) according to the manufac-
turer’s instructions. After 48 h, cells were lysed using PBS/1%
Triton X-100/20 mMMgCl2 containing protease inhibitor cock-
tails and DNaseI. Lysates were western blotted and proteins
detected using the following antibodies: anti-a-actin (Sigma,
A2066), anti-CYP2C19 (Novus Biologicals, NBP1-19698), anti-
CYP2D6 (Abnova, H00001565-B01P), anti-NDE1 (Proteintech,
10233-1-AP), anti-TRIOBP (Sigma, HPA019769) and anti-a-
tubulin (Sigma, T9026). IRDye secondary antibodies were
used (LI-COR) and the signal visualized using an Odyssey
CLx infrared imaging system(LI-COR).Proteinbandsof interest
were then isolated and quantified using IMAGE STUDIO software
(LI-COR). In the case of TRIOBP and CYP2D6, which are each
encoded for by multiple splice variants [46–48], the species at
72 and 56 kDa, respectively, were selected for analysis as they
are known to be biologically active [49,50]. In the case of
NDE1, all of the bands between 40 and 45 kDa, which are con-
sistent with its large number of known phosphorylation events
[51], were measured and pooled. All membranes were probed
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signal. Antibody signals were normalized to actin as a loading
control. Mean fold-changes between the control and miR-484-
treated samples were calculated from seven to eight technical
replicates, performed from the same batch of cells. Three inde-
pendent experiments of this type were then performed for
biological replication, and the results compared by two-tailed
paired Student’s t-test.Ta
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3.1. Replication of gene expression changes from
previous studies
In our previous analysis of gene expression in association with
DISC1 network variants using publicly available data on the
CEU (Utah residents with North andWestern European ances-
try) individuals, 86 genes were found to be differentially
expressed across the three DISC1 network variants that could
be directly replicated here (DISC1 rs821616, 18 genes; NDE1
rs4781678, 39 genes; NDE1 rs2242549, 29 genes) [30]. To
verify these results, made in a cohort of 30 individuals using
technical replications, these three variants were tested again,
this time using the Finnish family cohort. In total, six of the
gene expression changes previously reported could be repli-
cated, for the genes TRIOBP, ZNF500, KIAA1468, FCER1G,
SULT1A1 and two probes for the ST3GAL5 gene. These were
all in association with the status of the NDE1 gene locus
(rs2242549). In the previous analysis, NDE1 rs2242549 associ-
ated with changes in gene expression levels of 29 genes, thus
these six genes represent a 21% overlap.
3.2. Differentially expressed genes associated with
DISC1 pathway genotype
To further investigate the effect of DISC1 network variants on
gene expression,we used this Finnish family cohort as a discov-
ery sample to investigate the association of previously positive
DISC1 and NDE1 variants with genome-wide gene expression
of 11 976 probes. Notably, theNDE1 SNP rs2242549was signifi-
cantly associated with gene expression levels of a large number
of the probes (table 1 and electronic supplementarymaterial, S1,
figure S1). Specifically, 3824 probes representing 3314 distinct
genes showed uncorrected association with the NDE1 SNP
rs2242549 ( p  0.05), of which 2908 probes, representing 2542
distinct genes, were associated at FDR 5%. We also verified
that, despite the size of the discovery cohort, it had sufficient
power to detect the differentially expressed genes associated
with the rs2242549 variant (electronic supplementary material,
figure S2). By contrast, no probes were significantly altered in
expression levels in association at FDR 5% with either the
DISC1 variants tested (SNP rs821616 of the ‘HEP3’ haplotype
comprising rs751229 and rs3738401) or with the other NDE1
SNPs tested (rs4781678 or rs1050162).
3.3. Replication of gene expression changes associated
with NDE1 genotypes
In order to replicate these observations, we pursued three lines
of supporting evidence. Firstly, we noted that although all var-
iants tested are in high D’ linkage disequilibrium (LD) and thus
associated gene
rs881803
rs1050162 rs11130rs2242549rs6498567rs4781678
D¢ LD block
R2 LD blocks
predicted targets
NDE1
miR-484
rs2075512
expression changes
predicts cessation of
SSRIs metabolized by…CYP2C19
2276 312 2230
(either directly or indirectly)
increase levels of…
Figure 2. Schematic of the NDE1/miR-484 locus, and summary of findings from this study. The exonic structure of the NDE1 gene and the relative location of
miR-484, both on the þ strand of chromosome 16p13.11. For NDE1, exons present in all transcripts encoding full-length (300 amino acid or longer) NDE1 protein
are filled in with solid colour, while optionally transcribed exons are indicated with a striped pattern. The SNPs genotyped in the large Finnish family cohort are
labelled, with the LD block structure summarized (detail in electronic supplementary material, figure S3). SNPs analysed in this study are labelled in bold type, with
those SNPs that could only be studied in one of the sub-cohorts being further indicated with italics.
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high R2 LD with rs2242549 (rs1050162, R2 ¼ 0.88, n ¼ 1891
individuals genotyped at both loci; electronic supplementary
material, figure S3, as determined using Haploview [52,53])
and could, therefore, be assumed to act as an internal replication
of observations. Thus, within the discovery cohort, of the genes
whose expression levels were associated with rs2242549, 752
probes representing 695 genes were also significantly associa-
ted with rs1050162 prior to application of the FDR (p  0.05).
Secondly, we used existing data from a twin cohort for schizo-
phrenia from Finland [33,37] as a replication cohort, identifying
56 probes, each representing a different gene, with replicable
significant alteration in their expression levels associated with
rs2242549 (table 1 and electronic supplementary material, S1).
Finally, we used the publicly available database GTEx as an
additional independent replication cohort, from which we
were able to directly test 2651 of the 3314 genes identified
(those probes with an official gene name), confirming that
180 genes also display significant gene expression changes rela-
ted to the NDE1 SNP rs2242549 in this database (table 1 and
electronic supplementary material, S1).
In total, 794 probes representing 719 genes had supporting
evidence from at least one additional source for their changes
in expression related to the NDE1 variant rs2242549, of
which 76 probes from 73 genes had supporting evidence
frommore than one source, and four probes from independent
genes (ITGB5, OVGP1, PGRMC1, TST) had supporting evi-
dence from all three sources, that is SNPs in high LD in the
discovery cohort, as well as independent replication cohorts
of Finnish twins and the GTEx database.
3.4. Enrichment of miR-484 target genes among genes
whose expression is associated with NDE1
genotype
The finding that expression levels of such a large number of
genes could be altered by a single genetic locus was surprising,
especially given that the principal functions of the NDE1
protein are not known to be in gene regulation. The NDE1
locus also encodes for a microRNA (miR-484), which is located
on a non-coding 50 exon of the longest splice variant of theNDE1 gene (figure 2). Since the major function of microRNAs
is in the regulation of expression of other genes it is the most
likely explanation for the sheer number of expression changes
observed to associate with these SNPs. We therefore investi-
gated whether the set of genes whose expression is altered by
these NDE1 SNPs overlapped with those genes predicted to
be targets of miR-484.
Using the miRWalk database [41], 16 027 gene targets are
predicted for miR-484, of which 2588 are predicted by at least
six or more of the 12 independent prediction programs used
in the database (data collated June 2016). Upon examining
the list of genes whose expression is altered by SNPs in the
NDE1 locus at FDR 5% in our discovery cohort, these
probes were indeed seen to be enriched for predicted targets
of miR-484 ( p ¼ 3  1028). Employing the same tests to the
three replication studies described above, the enrichment in
miR-484 targets was also present for the set of these genes
whose expression level is significantly associated with the gen-
otype of both NDE1 SNPs rs2242549 and rs1050162 (which
were in high LD), and among those genes which could also
be observed in the replication twin cohort. In contrast, they
were not enriched among those genes replicated by data
from the GTEx database (table 1).3.5. Medication cessation associated with NDE1
genotype
In our previously published analysis we found NDE1 geno-
types that significantly associated with expression levels of
targets for particular medications relevant to mental health
[30]. We therefore tested whether NDE1 genotypes were also
associatedwith cessation of specific medications in a discovery
cohort consisting of all affected individuals from the Finnish
family cohort. Screening all of the medications frequently
used within this discovery cohort, we observed an association
between NDE1 rs4781678 genotype and early cessation of use
of the antipsychotic levomepromazine (OR ¼ 4.13 per C allele;
95% CI ¼ 1.72–9.91; p ¼ 0.00090). When analysed in inter-
action with gender, association was further observed across
NDE1 genotypes with early cessation of the use of diazepam
and citalopram (electronic supplementary material, table S2),
Table 2. Results for the association of NDE1 variants with groups of
medications based on their metabolism by the CYP2C19 enzyme and/or
selective serotonin reuptake inhibitor (SSRI) class status, showing the p-values
and odds ratios (and 95% CIs) for the interaction model. p-Values  0.01 are
below the Bonferroni correction threshold for the ﬁve groups tested. p-Values
and their respective ORs that are below the Bonferroni threshold are in bold.
Medications included in each group analysis can be found in the electronic
supplementary material, ﬁgure S4 and table S3.
NDE1 variant
SNP SNP  gender
p-value p-value OR (95% CI)
all psychoactive drugs metabolized by CYP2C19 (N ¼ 510–581, no. of
instances: 843–945)
rs4781678 0.79 0.90 0.97 (0.55–1.69)
rs2242549 0.56 0.74 1.10 (0.64–1.86)
rs881803 0.29 0.15 1.53 (0.86–2.73)
rs2075512 0.64 0.79 0.93 (0.53–1.63)
haplotype 0.35 0.73 1.10 (0.63–1.93)
SSRIs (N ¼ 357–402, no. of instances: 496–563)
rs4781678 0.31 0.033 0.43 (0.20–0.93)
rs2242549 0.92 0.031 0.46 (0.23–0.93)
rs881803 0.41 0.29 0.67 (0.32–1.40)
rs2075512 0.97 0.010 0.37 (0.17–0.79)
haplotype 0.87 0.029 0.42 (0.19–0.91)
SSRIs metabolized by CYP2C19 (N ¼ 282–318, no. of instances:
357–395)
rs4781678 0.42 0.003 0.27 (0.11–0.64)
rs2242549 0.47 0.006 0.30 (0.13–0.70)
rs881803 0.51 0.064 0.44 (0.19–1.05)
rs2075512 0.39 0.005 0.31 (0.13–0.70)
haplotype 0.95 0.006 0.30 (0.13–0.71)
SSRIs not metabolized by CYP2C19 (N ¼ 123–145, no. of instances:
142–169)
rs4781678 0.48 0.71 1.36 (0.27–6.87)
rs2242549 0.30 0.58 1.37 (0.45–4.23)
rs881803 0.58 0.23 2.24 (0.60–8.38)
rs2075512 0.10 0.88 0.88 (0.19–4.13)
haplotype 0.66 0.77 1.25 (0.27–5.76)
non-SSRIs metabolized by CYP2C19 (N ¼ 318–355, no. of instances:
411–459)
rs4781678 0.24 0.0051 3.33 (1.44–7.73)
rs2242549 0.62 0.0013 3.42 (1.61–7.25)
rs881803 0.63 0.00030 5.82 (2.25–15.0)
rs2075512 0.92 0.0064 3.63 (1.44–9.17)
haplotype 0.22 0.00030 4.93 (2.07–11.76)
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enzyme, CYP2C19 (cytochrome P450 2C19, electronic sup-
plementary material, table S3) [54–57]. We therefore asked
whether NDE1 genotype was associated with the subset of
medications metabolized by the CYP2C19 enzyme. Since
four out of seven of the drugs metabolized by CYP2C19 were
selective serotonin reuptake inhibitors (SSRIs), we studied
these as a separate group as well as further separated based
on CYP2C19 metabolism. No significant interaction was
observed for the grouping of all drugs metabolized by
CYP2C19, however a genotype by gender interaction was
noted when all SSRIs were grouped together (rs2075512,
OR ¼ 0.37; 95% CI ¼ 0.17–0.79; p ¼ 0.010). When all SSRIs
metabolized by CYP2C19 were tested, this genotype by
gender interaction became significant (ranging from: OR ¼
0.27 to 0.31; 95% CI ¼ 0.11 to 0.13–0.64 to 0.71; p ¼ 0.0030 to
0.0060) for four out of the five NDE1 markers tested, while
no interaction was noted for SSRIs not metabolized by
CYP2C19 (table 2 and electronic supplementary material,
figure S4). We analysed the remaining drugs metabolized by
CYP2C19 together as another grouping (non-SSRIs metab-
olized by CYP2C19). Interestingly, a significant interaction
was observed (ranging from: OR ¼ 3.33 to 5.82; 95% CI ¼
1.44 to 2.25–7.25 to 15.0; p ¼ 0.0013 to 0.00030) for all five
NDE1markers (table 2 and electronic supplementary material,
figure S4). In this case, however, the gender effect is reversed,
with SNPs being associated with cessation among females, in
contrast to SSRIs metabolized by CYP2C19, for which SNPs
were associated with cessation among males.
3.6. The effect of miR-484 on CYP2C19 in cultured cells
Given that a major effect of the NDE1 locus variants examined
here seems to be to alter the expression of genes targeted by
miR-484, presumably due to altered expression of this miR-
484, we hypothesized that the pharmacological consequences
of these variants were also likely to occur through miR-484.
For this to be the case, miR-484 would need to affect the
levels of CYP2C19 protein expression, and thus be able to
alter its metabolic activity effects on psychoactive medication.
We therefore conducted a proof-of-principle experiment in
NLF human neuroblastoma cells, into which we transfected a
mimic of the mature form of human miR-484. Protein levels of
CYP2C19 were significantly upregulated following miR-484
transfection, when compared with transfection with a negative
control microRNA (figure 3). In contrast, no effect on the
expression of another principalmetabolizing enzyme of psycho-
active medications, CYP2D6, was seen, indicating that this is a
specific effect. That the levels of these proteins are altered, in
a manner that closely matches to the pharmacogenetic data,
strongly implies that miR-484 influences the expression of
CYP2C19, but not CYP2D6, transcripts, although additional
data at the transcript level would be required to confirm this.
Finally, we also used the same system to investigate two
proteins that are predicted targets of miR-484, each of which
illustrates a potential false negative in this study, possibly as
a result of power limitations. The first of these, TRIOBP, was
observed to be significant in our discovery cohort but not in
the replication cohorts, while the other is NDE1 itself, which
was highly significant in the larger GTEx database (b ¼ 0.24;
s.e. ¼ 0.037; t-statistic ¼ 6.6; p ¼ 2.3  10210), but not orig-
inally observed in our discovery cohort. TRIOBP was further
selected as it is also an example of the six genes whoseexpression was associated with NDE1 variation both here
and in our previous analysis [30]. In both cases, protein
levels were subtly, but statistically significantly, altered follow-
ing treatmentwith themiR-484mimic (figure 3), in comparison
to the negative control microRNA.
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Figure 3. The effect of a miR-484 mimic on protein expression in human NLF neuroblastoma cells. (a) Sample western blots showing levels of six proteins in the
lysates of cells which had been transfected with either a mimic of miR-484 or with a negative control microRNA. (b) Quantification of three independent
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Here we have demonstrated that variations within the NDE1
locus, encoding a protein of the DISC1 network of protein inter-
action partners, can affect both gene expression levels and
medication usage of psychoactive drugs used to treat major
mental illnesses. Specifically, two SNPs in high LD are associ-
ated with replicable expression changes in a large number of
genes, and with early cessation of psychoactive medications
metabolized by CYP2C19 in a gender-dependent manner. We
propose that these observations are linked through the involve-
ment of miR-484. This microRNA is encoded for within the 50
untranslated exon of the longest splice variant of NDE1, and
the one which is most abundantly expressed, at least in cell cul-
ture [58]. Notably, the list of genes whose expression changes
are associated with these NDE1 locus variants is significantly
enriched for predicted targets of the microRNA, while
expression of the CYP2C19 protein has been demonstrated
in vitro to be significantly increased following addition of a
mimic of mature human miR-484. This latter result was
obtained from neuroblastoma cells. While such immortalized
cells represent an atypical genetic environment, and some
caution must be taken in directly applying them to in vivo situ-
ations, they represent a useful tool to performproof-of-principle
experiments in a reductionist manner. Nevertheless, the most
promising explanation for the observations described here
would, therefore, be that variation at the NDE1 locus affects
gene expression and medication metabolism in large part
through effects of the variant on miR-484, and this may even
be behind our prior observations at this locus of association to
schizophrenia. It is interesting to note that a 1.45-fold increase
in miR-484 has previously been reported in the superior tem-
poral gyri of patients with schizophrenia [59]. Regarding the
mechanism by which SNPs in the NDE1 locus may affect
expression of miR-484, it is noteworthy that miR-484 is tran-
scribed from the same strand as NDE1, with both themicroRNA and its promoter [60] being found within a 50
untranslated exon of NDE1, which is included in some but
not all NDE1 splice variants. It is therefore very likely that
any event which affects either the expression or alternate spli-
cing of NDE1 would also impact upon miR-484 expression.
That many of the SNPs of the NDE1 haplotypes are found in
the 30-most intron of NDE1 (figure 2), which contains many
motifs that regulateNDE1 splicing [61], therefore allows specu-
lation that the SNPs could affect miR-484 expression indirectly
through modulation of NDE1 splicing events.
The 16p13.11 locus, in which the NDE1 gene is found,
is prone to copy number variations (CNVs), with these
16p13.11 CNVs having been repeatedly associated with psy-
chiatric and neurological disorders [19–22,28]. This locus
contains multiple genes, however NDE1 has been considered
among the most promising candidates to be involved in these
disorders due to its known critical role in neurodevelopment
(reviewed: [62]). Therefore, our observations here, although
of specific SNPs at the NDE1 locus, highlight disruption of
miR-484 as a potential functional consequence also of those
CNVs. These results partially parallel recent findings that
expression of mature miR-484 led to alterations in neural
progenitor proliferation and differentiation, as well as behav-
ioural changes in mice, thus implicating the microRNA in the
phenotypes associated with 16p13.11 duplication [29]. While
NDE1 over-expression was not seen to have a gross effect on
neuronal progenitor proliferation under similar circumstances,
given the severe neurological consequences of biallelic disrup-
tion of the NDE1, but not miR-484, reading frame [24–27],
there is still a potential role for NDE1 in the conditions associ-
ated with 16p13.11 duplication. Additionally, relatively mild
phenotypic effects would be needed to explain the fact that
while associated with schizophrenia risk, most carriers of the
CNV do not develop the condition [19–22]. Nevertheless, it
can be speculated that the mechanism implicated here through
SNP association, that miR-484 drives large gene expression
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of this locus.
This study initially sought to replicate our previous work
on the effect of DISC1 network variants on gene expression
changes in the general population, using publicly available
data on theCEU (Utah residentswithNorth andWestern Euro-
pean ancestry) individuals [30]. Of these previously identified
86 genes, we were able to replicate the observed changes in
expression of six genes, including expression changes of two
probes for ST3GAL5 and a probe for TRIOBP, the only one
of these genes to be a predicted target for miR-484. All of
these were in association with the NDE1 SNP rs2242549,
and represented a 21% overlap with the findings from the
prior study [30]. When we tested for gene expression altera-
tions across the genome we identified a large number of
probes (n ¼ 2908) representing 2542 genes whose expression
levels associated with variants at the NDE1 locus, specifically
with the SNP rs2242549. A large proportion of these (752 out
of 3824 probes, 695 out of 3314 genes) were significantly altered
by another NDE1 SNP (rs1050162), which is in high LD
with rs2242549. Yet replication attempts in independent
cohorts, although providing validation for some genes (56 in
an independent Finnish schizophrenia cohort and 180 using
the GTEx database), did not provide unilateral confirmatory
evidence, with the exception of four genes (ITGB5, OVGP1,
PGRMC1, TST) identified across all three datasets tested.
This lack of replication, combined with our new observations
and their biological relevance through miR-484 to the NDE1
locus, suggests that, although the variants studied here are
common to many populations, their relationship to potential
functional mutations at this locus, and their specific biologi-
cal consequences associated with schizophrenia and gene
expression changes, may be unique to this Finnish family
cohort [63]. This population difference may account for the
lack of replication of most of the previously observed genes
in the CEU population [30], and the lack of enrichment for
miR-484 targets in the GTEx database. This is consistent with
DISC1 variation playing a genetically heterogeneous role in
the general incidence of schizophrenia, lacking common
illness-associated variations which could be detected by
genome-wide association studies [15,16] of global populations,
but providing strong evidence for a role in the conditionwithin
specific populations and family studies [63].
Another potential explanation for our inability to replicate
our observations across cohorts is the fact that our power to
detect these effects is reduced due to the small sample sizes
used here. Although we have demonstrated that we have
80% power in our discovery cohort to detect large changes in
gene expression (D ¼ 0.52), this is for our observed 90th
percentile of the standard deviation for all genes from our
data (s ¼ 0.53) (electronic supplementary material, figure S2);
probes with smaller standard deviations would not be detect-
able, either for these probes in replication cohorts or for other
probes in the discovery cohort. Thus, we verified our findings
in a neuroblastoma cell culture model for two genes, which
were predicted to be targets ofmiR-484, but provided inconsist-
ent observations. The first, TRIOBP, was observed in our
previously published study of the publicly available data on
the CEU (Utah residents with North and Western European
ancestry) individuals [30] and was replicated in our discovery
family cohort, but not in either the twin or GTEx replication
cohorts. In contrast, the second, NDE1, was not observed in
any of the Finnish cohorts but was strongly implicated in thelarger GTEx data where NDE1 expression levels were strongly
associated with the NDE1 SNP rs2242549 genotype (b ¼ 0.24;
s.e. ¼ 0.037; t-statistic ¼ 6.6; p ¼ 2.3  10210). The proteins
encoded for by these genes were each found to be significantly
increased by the presence of the mimic of miR-484. Such a ver-
ification analysis would be required for all genes implicated in
this study. However, with such a large number of genes ident-
ified this was not feasiblewith the cell culture model used here.
When the DISC1 network was studied with respect to
treatment, the NDE1 locus again demonstrated association,
specifically in interaction with gender for drugs metabolized
by CYP2C19. The degree of expression of cytochrome P450
enzymes in lymphocytes was too low to allow us to investigate
potential changes in expression level in our family data.
Instead we demonstrated in a cell culture model that miR-484
is capable of increasing the expression of CYP2C19, but not
that of another major metabolizing enzyme for psychoactive
drugs, CYP2D6. The miRWalk database does not robustly
predict either enzyme to be a target for miR-484, thus the
mechanism of this action needs to be further investigated.
The results from the cell culture assays clearly indicate, how-
ever, that miR-484 is capable of affecting the expression level
of CYP2C19, suggesting that the mechanism through which
the locus confers risk and alters medication usage could be
the same. In spite of the lack of confident prediction, a direct
effect of miR-484 on the CYP2C19 locus remains the simplest
explanation for these observations, although indirect effects
remain possible.
In the case of medication use, we employed a dichoto-
mous variable based on a cut-off of ceasing to use the
prescribed medication after three months or less. This was
designed to indicate that a treatment was either not con-
sidered to be working or else was having side effects which
were too severe and its use was, therefore, stopped. Since
the cell culture experiment showed that CYP2C19 protein
expression is increased by miR-484, it can be hypothesized
that the medications are more rapidly metabolized in individ-
uals carrying these variants, leading to a reduced efficacy of
those treatments. Interestingly, the genetic effects on medi-
cation differ depending on both class of drug and gender.
Males carrying the risk alleles had a higher probability of ces-
sation of use for SSRIs metabolized by CYP2C19, while
females carrying the risk alleles had an increased probability
of cessation for non-SSRI drugs that are metabolized by
CYP2C19. Although the mechanism for these effects remains
unclear at this time, it is noteworthy that the original associ-
ation between the NDE1 locus and schizophrenia in these
families was significant only in females [3]. Taken together
this implies that one or more gender-specific effects act as
modifying factors in conjunction with the NDE1/miR-484
locus, although this cannot be easily modelled in our cell
culture system.
Here, through the identification of altered gene expression
patterns that led to the functional implication of miR-484,
which is coded on an untranslated exon of the primary iso-
form of NDE1, we identified a means by which genetic
variation in the DISC1 network can not only increase risk
of major mental illnesses, but also how those same variants
can alter treatment response to specific psychoactive medi-
cations through the regulation of their metabolizing
enzyme. This study has, therefore, provided new biological
insight into psychiatric disorders for which novel medi-
cations could be designed, as well as suggesting that
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miR-484 locus may have potential value in the targeting of
current therapies.
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